EUVIMEDEUVIMED entdecken
Mixed-Methods-StudieOpen Access · CC BY 4.0

Perspectives of pediatric oncologists on referral for CAR-T therapy: a mixed methods pilot study

Anurekha G Hall iD, Devan M Duenas, Jenna Voutsinas, Qian Wu, Adam J Lamble, Elizabeth Gruber, Benjamin Wilfond, Julie R Park iD, Anurag K Agrawal, Jonathan M Marron

JNCI Cancer Spectrum · 2024

DOI: 10.1093/jncics/pkae063 ↗

Kurz gefasst

Mixed-Methods-Studie in der Zeitschrift JNCI Cancer Spectrum, 2024. Verfasst von Anurekha G Hall und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, University of Washington, Seattle Children's Hospital, Seattle, WA, USA. Hauptthemen laut MEDLINE: Referral and Consultation, Oncologists, Immunotherapy, Adoptive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NIH HHS, Conquer Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Receipt of chimeric antigen receptor T-cell (CAR-T) therapy at an institution different from the primary oncologist’s institution is a complex, multistep process. Referral by oncologists plays an important role in the process but may be susceptible to bias.

Methods

Oncologists who previously referred patients for CAR-T therapy at 5 pediatric hospitals were sent surveys by email exploring their CAR-T referral practices. Descriptive statistics were generated, and multivariate analyses examined associations among oncologist characteristics, familiarity with CAR-T therapy, and referral practices. We conducted semistructured interviews with a subset of participants and used thematic analysis to code transcripts.

Results

Sixty-eight oncologists completed the survey; 77% expressed being “very familiar” with CAR-T therapy. Hispanic oncologists and oncologists at institutions with 50 or fewer new diagnoses per year were more likely to identify as less familiar with CAR-T therapy (odds ratio [OR] = 64.3, 95% confidence interval [CI] = 2.45 to 10 452.50, P = .04 and OR = 24.5, 95% CI = 3.3 to 317.3, P = .005, respectively). In total, 38% of respondents considered nonclinical features (compliance, social support, resources, insurance, language, education, and race or ethnicity) influential in referral decisions. Oncologists who were Hispanic and oncologists who had been practicing for 20 or more years were more likely to consider these features significantly influential (OR = 14.52, 95% CI = 1.49 to 358.66, P = .04 and OR = 6.76, 95% CI = 1.18 to 50.5, P = .04). Nine oncologists completed in-depth interviews; common themes included barriers and concerns regarding CAR-T therapy referral, the value of an established relationship with a CAR-T therapy center, and poor communication after CAR-T therapy.

Conclusions

Nearly 40% of oncologists consider nonclinical features significantly influential when deciding to refer patients for CAR-T therapy, raising concern for bias in the referral process. Establishing formal partnerships with CAR-T therapy centers may help address physician barriers in referral.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Referral and ConsultationOncologistsImmunotherapy, AdoptiveHumansPilot ProjectsMaleFemaleHispanic or LatinoAttitude of Health PersonnelHospitals, PediatricReceptors, Chimeric AntigenChildNeoplasmsMedical OncologySurveys and QuestionnairesPractice Patterns, Physicians'PediatricsAdult

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Division of Hematology and Oncology, University of Washington, Seattle Children's Hospital, Seattle, WA, USA.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Treuman Katz Center for Pediatric Bioethics and Palliative Care, Seattle Children's Research Institute, Seattle, WA, USA.
  • Seattle Children's Therapeutics, Seattle, WA, USA.
  • Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Division of Hematology and Oncology, UCSF Benioff Children's Hospital Oakland, Oakland, CA, USA.

ORCID-Profile: Anurekha G Hall, Julie R Park

Förderung

  • NCATS NIH HHS
  • NIH HHS
  • Conquer Cancer Foundation
  • National Institutes of Health

Zitieren

APA

Hall, A. G., Duenas, D. M., Voutsinas, J., Wu, Q., Lamble, A. J., Gruber, E., Wilfond, B., Park, J. R., Agrawal, A. K., & Marron, J. M. (2024). Perspectives of pediatric oncologists on referral for CAR-T therapy: a mixed methods pilot study. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkae063

Vancouver

Hall AG, Duenas DM, Voutsinas J, Wu Q, Lamble AJ, Gruber E, et al. Perspectives of pediatric oncologists on referral for CAR-T therapy: a mixed methods pilot study. JNCI Cancer Spectrum. 2024. doi:10.1093/jncics/pkae063

BibTeX
@article{Hall2024,
  author = {Hall, Anurekha G and Duenas, Devan M and Voutsinas, Jenna and Wu, Qian and Lamble, Adam J and Gruber, Elizabeth and Wilfond, Benjamin and Park, Julie R and Agrawal, Anurag K and Marron, Jonathan M},
  title = {Perspectives of pediatric oncologists on referral for CAR-T therapy: a mixed methods pilot study},
  journal = {JNCI Cancer Spectrum},
  year = {2024},
  doi = {10.1093/jncics/pkae063}
}
Kostenlos starten →